CHEK2 and ductal breast carcinoma in situ: The median follow-up among 564 women with DCIS was 156 months (range 1–270, SD 62.7), including 166 months (range 18–258, SD 54.6) for CHEK2 mutation carriers versus 156 (range 1–270, SD 63.4) for non-carriers (p = 0.3, Mann-Whitney test).